{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T06:15:28Z","timestamp":1788070528776,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Weifang Health Commission's scientific research program","award":["No. WFWSJK-2025-17"],"award-info":[{"award-number":["No. WFWSJK-2025-17"]}]},{"name":"Weifang Health Commission's scientific research program","award":["No. WFWSJK-2023-240"],"award-info":[{"award-number":["No. WFWSJK-2023-240"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10067-026-08308-3","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:16:03Z","timestamp":1784913363000},"page":"5421-5430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Janus kinase inhibitor exposure and acute coronary event patterns in rheumatoid arthritis: a treatment-aware retrospective study"],"prefix":"10.1007","volume":"45","author":[{"given":"Yuwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiduo","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-9984","authenticated-orcid":false,"given":"Sheng-Guang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangcheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"9","key":"8308_CR1","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u20132581. https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"issue":"9","key":"8308_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71(9):1524\u20131529. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200726","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8308_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76(1):17\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209775","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8308_CR4","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"DH Solomon","year":"2015","unstructured":"Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR et al (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 67(6):1449\u20131455. https:\/\/doi.org\/10.1002\/art.39098","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"8308_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM et al (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70(3):482\u2013487. https:\/\/doi.org\/10.1136\/ard.2010.135871","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8308_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"8308_CR7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K et al (2021) American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 73(7):1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"8308_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"issue":"1","key":"8308_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR et al (2023) Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis 82(1):119\u2013129. https:\/\/doi.org\/10.1136\/ard-2022-222259","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8308_CR10","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/art.43188","volume":"77","author":"R Aymon","year":"2025","unstructured":"Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D et al (2025) Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries. Arthritis Rheumatol 77(9):1194\u20131204. https:\/\/doi.org\/10.1002\/art.43188","journal-title":"Arthritis Rheumatol"},{"key":"8308_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152563","volume":"69","author":"A Pugliesi","year":"2024","unstructured":"Pugliesi A, Oliveira DGC, Filho VAS, Machado JO, Pereira AG, Bichuette JCS et al (2024) Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: systematic review and traditional and Bayesian network meta-analysis of randomized clinical trials. Semin Arthritis Rheum 69:152563. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152563","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 1","key":"8308_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.31138\/mjr.171023.rof","volume":"35","author":"S Partalidou","year":"2024","unstructured":"Partalidou S, Patoulias D, Deuteraiou K, Avgerou P, Kitas G, Tzitiridou-Chatzopoulou M et al (2024) Risk of major adverse cardiovascular events and venous thromboembolism with JAK inhibitors versus TNF inhibitors in rheumatoid arthritis patients: a systematic review and meta-analysis. Mediterr J Rheumatol 35(Suppl 1):10\u201319. https:\/\/doi.org\/10.31138\/mjr.171023.rof","journal-title":"Mediterr J Rheumatol"},{"issue":"2","key":"8308_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4078\/jrd.2024.0104","volume":"32","author":"SM Ahn","year":"2025","unstructured":"Ahn SM, Kim S, Kim YJ, Hong S, Lee CK, Yoo B et al (2025) Risk of acute myocardial infarction associated with anti-rheumatic agents in patients with rheumatoid arthritis: a nationwide population-based case-control study. J Rheum Dis 32(2):113\u2013121. https:\/\/doi.org\/10.4078\/jrd.2024.0104","journal-title":"J Rheum Dis"},{"issue":"9596","key":"8308_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"issue":"20","key":"8308_CR15","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","volume":"138","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA et al (2018) Fourth universal definition of myocardial infarction (2018). Circulation 138(20):e618\u2013e651. https:\/\/doi.org\/10.1161\/CIR.0000000000000617","journal-title":"Circulation"},{"issue":"1","key":"8308_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth D (1993) Bias reduction of maximum likelihood estimates. Biometrika 80(1):27\u201338. https:\/\/doi.org\/10.1093\/biomet\/80.1.27","journal-title":"Biometrika"},{"issue":"16","key":"8308_CR17","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze G, Schemper M (2002) A solution to the problem of separation in logistic regression. Stat Med 21(16):2409\u20132419. https:\/\/doi.org\/10.1002\/sim.1047","journal-title":"Stat Med"},{"issue":"1","key":"8308_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","volume":"188","author":"F Li","year":"2019","unstructured":"Li F, Thomas LE, Li F (2019) Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 188(1):250\u2013257. https:\/\/doi.org\/10.1093\/aje\/kwy201","journal-title":"Am J Epidemiol"},{"issue":"28","key":"8308_CR19","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34(28):3661\u20133679. https:\/\/doi.org\/10.1002\/sim.6607","journal-title":"Stat Med"},{"issue":"6917","key":"8308_CR20","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","volume":"420","author":"P Libby","year":"2002","unstructured":"Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868\u2013874. https:\/\/doi.org\/10.1038\/nature01323","journal-title":"Nature"},{"issue":"9","key":"8308_CR21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/ard-2023-223916","volume":"82","author":"R Fleischmann","year":"2023","unstructured":"Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C et al (2023) Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis 82(9):1130\u20131141. https:\/\/doi.org\/10.1136\/ard-2023-223916","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8308_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W et al (2022) Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 81(3):335\u2013343. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221276","journal-title":"Ann Rheum Dis"},{"key":"8308_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijcard.2018.02.116","volume":"266","author":"F Dentali","year":"2018","unstructured":"Dentali F, Nigro O, Squizzato A, Gianni M, Zuretti F, Grandi AM et al (2018) Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: a systematic review and meta-analysis of the literature. Int J Cardiol 266:31\u201337. https:\/\/doi.org\/10.1016\/j.ijcard.2018.02.116","journal-title":"Int J Cardiol"},{"issue":"12","key":"8308_CR24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"issue":"3","key":"8308_CR25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480\u2013489. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8308_CR26","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard-2023-224185","volume":"82","author":"H So","year":"2023","unstructured":"So H, Lam TO, Meng H, Lam SHM, Tam LS (2023) Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis 82(11):1387\u20131393. https:\/\/doi.org\/10.1136\/ard-2023-224185","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8308_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-016-1077-z","volume":"18","author":"Y Meissner","year":"2016","unstructured":"Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S et al (2016) Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther 18(1):183. https:\/\/doi.org\/10.1186\/s13075-016-1077-z","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08308-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08308-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08308-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T06:06:10Z","timestamp":1788069970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08308-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8308"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08308-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the Ethics Committee of Weifang People\u2019s Hospital (approval number: KYLL20251029-3). The requirement for informed consent was waived because this was a retrospective study using de-identified clinical data.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}